Chemistry:Alnodesertib
From HandWiki
Alnodesertib is an investigational new drug that is being developed by Artios Pharma for the treatment of solid tumours.[1][2] It is an ataxia telangiectasia and Rad3 related (ATR) protein inhibitor.[1][3][4]
Clinical trials
Alnodesertib is currently in clinical trials for solid tumors.[5] Another study was terminated "not for reasons affecting the benefit-risk balance".[6]
References
- ↑ 1.0 1.1 "Alnodesertib - Artios Pharma". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800061422.
- ↑ "WHO proposed international nonproprietary names list". World Health Organization. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf?sfvrsn=8812b861_3&download=true.
- ↑ "Resistance-centered pharmacology of DNA damage response-targeted therapy: Mechanisms, predictive biomarkers, and biomarker-guided adaptive treatment strategies in solid tumors". Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 201. June 2026. doi:10.1016/j.biopha.2026.119670. PMID 42314345.
- ↑ "Targeting ATR-CHK1 and ATM-CHK2 Axes in Pancreatic Cancer-A Comprehensive Review of Literature". International Journal of Molecular Sciences 27 (3): 1152. January 2026. doi:10.3390/ijms27031152. PMID 41683580.
- ↑ Clinical trial number NCT04657068 NCT04657068 for "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors" at ClinicalTrials.gov
- ↑ Clinical trial number NCT05798611 for "Study of ART0380 in Patients With Biologically Selected Solid Tumors" at ClinicalTrials.gov
 |  |
